Brief: Sensei Announces New Preclinical Data For SNS-101
31/08/2022 12:57
Aug 31 (Reuters) - Sensei Biotherapeutics Inc SNSE.O :
* SENSEI BIOTHERAPEUTICS ANNOUNCES NEW PRECLINICAL DATA
DEMONSTRATING FAVORABLE PHARMACOKINETIC AND IMMUNOLOGIC EFFECTS
OF SNS-101, A PH-SELECTIVE VISTA-BLOCKING ANTIBODY
* SENSEI BIOTHERAPEUTICS INC - CO PLANS TO FILE AN IND
DURING
FIRST HALF OF 2023
Source text for Eikon: ID:nGNXc3s0Yn
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics
See all newsU.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
Faeth Therapeutics rises after FDA grants fast-track status for cancer drug
Brief: Faeth Therapeutics Announces FDA Grant Of Fast Track Designation For Piktor Plus Paclitaxel In Biomarker-Selected Advanced Endometrial Cancer
Brief: Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments